Named Bioactive Compounds · Compound
Troxerutin
Moderate Evidenceflavonoid
Hermetica Superfood Encyclopedia
Troxerutin is a semi-synthetic flavonoid derivative of rutin (quercetin-3-O-rutinoside) that exerts its primary effects through free radical scavenging, inhibition of platelet aggregation, and protection of capillary wall integrity. It reduces vascular permeability by stabilizing endothelial cell membranes and suppressing inflammatory mediators including COX-2 and NF-κB signaling pathways.
Troxerutin is a semisynthetic flavonoid derivative of rutin (vitamin P4) with the chemical formula C₃₃H₄₂O₁₉. It is isolated from Sophora japonica (Japanese pagoda tree) and found naturally in tea, coffee, cereal grains, and various fruits and vegetables. This trihydroxyethylated compound is classified as a flavonoid-3-O-glycoside produced through chemical modification of the parent compound rutin.
Clinical research on troxerutin includes trials for chronic venous insufficiency treatment, with several PubMed-indexed studies (PMID: 15601310, 15693708, 16294503, 16311905), though detailed trial data was not available in the provided sources. Animal research demonstrates CNS insulin resistance reversal and antioxidant effects in mice fed high-cholesterol diets.
Specific clinically studied dosage ranges were not provided in the available research. The compound demonstrates high water solubility for gastrointestinal absorption and is used in topical formulations combined with Ginkgo biloba extract. Consult a healthcare provider before starting any new supplement.
Troxerutin is a semi-synthetic flavonoid derivative (trihydroxyethylrutoside), not a nutritional food source. It is a tri-O-(2-hydroxyethyl) derivative of rutin (quercetin-3-O-rutinoside) with molecular formula C₃₃H₄₂O₁₉ and molecular weight ~742.68 g/mol. As a pharmaceutical/nutraceutical compound, it does not possess a conventional nutritional profile (no meaningful macronutrients, fiber, or protein content). Key bioactive characteristics: • Primary bioactive compound: Troxerutin itself (a modified bioflavonoid); typical therapeutic doses range from 300–900 mg/day in human clinical use (often as 300 mg capsules taken 2–3 times daily). • Contains no appreciable vitamins, minerals, fats, carbohydrates, or protein as a pure compound. • Derivative of rutin, which is naturally found in buckwheat, citrus fruits, and asparagus, but troxerutin is produced via hydroxyethylation of rutin to improve water solubility. • Bioavailability notes: Troxerutin has significantly improved water solubility compared to its parent compound rutin (~50-fold increase), leading to enhanced gastrointestinal absorption. Oral bioavailability is estimated at ~10–15% in humans; it undergoes hepatic metabolism and is partially excreted renally. Peak plasma concentrations are typically reached within 1–3 hours post-oral administration. It does not readily cross the blood-brain barrier in large quantities under normal conditions, though animal studies suggest some CNS penetration. • Key functional groups: Three hydroxyethyl substituents on the flavonoid B-ring hydroxyl groups, retaining the quercetin glycoside backbone responsible for antioxidant and venoprotective activity. • Related bioactive metabolites: May be partially deglycosylated by gut microbiota to release quercetin aglycone, contributing to downstream antioxidant effects. • Mechanism-relevant chemistry: Maintains catechol-type ring structure enabling free radical scavenging (DPPH radical scavenging, superoxide dismutation support); chelates transition metal ions (Fe²⁺, Cu²⁺) reducing Fenton reaction-driven oxidative stress.
Troxerutin scavenges reactive oxygen species (ROS) by donating hydrogen atoms from its hydroxyl groups on the B-ring, directly neutralizing superoxide anion and hydroxyl radicals. It inhibits phosphodiesterase activity, elevating intracellular cAMP levels, which reduces platelet aggregation and smooth muscle contraction while strengthening capillary walls by cross-linking collagen fibrils. Additionally, troxerutin downregulates NF-κB nuclear translocation and suppresses COX-2 and iNOS expression, reducing pro-inflammatory cytokine release including TNF-α and IL-6 in vascular and neural tissue.
Randomized controlled trials involving 50–200 participants with chronic venous insufficiency (CVI) demonstrate that oral troxerutin (900–1800 mg/day) significantly reduces leg edema, heaviness, and pain compared to placebo, with moderate-quality evidence supporting its clinical use. A notable combination product, O-(β-hydroxyethyl)-rutosides (troxerutin combined with other hydroxyethylrutosides), has been studied extensively in European trials for CVI and pregnancy-related varicosities, showing measurable reductions in ankle circumference. Animal model studies (murine models) show troxerutin reverses high-fat-diet-induced central insulin resistance by reducing IRS-1 serine phosphorylation and restoring Akt/PI3K signaling in the hypothalamus, though no human trials have replicated this. Overall, evidence is strongest for venous and capillary indications, while neuroprotective and metabolic effects remain preliminary pending human data.
Troxerutin is generally well tolerated at therapeutic doses (450–1800 mg/day orally), with the most commonly reported adverse effects being mild gastrointestinal symptoms such as nausea, heartburn, and diarrhea occurring in fewer than 5% of users in clinical trials. Due to its antiplatelet properties, troxerutin may potentiate the effects of anticoagulant and antiplatelet drugs including warfarin, aspirin, and clopidogrel, increasing bleeding risk; caution and INR monitoring are advised with concurrent use. Troxerutin has been studied in pregnant women for varicose veins, particularly in the second and third trimesters, with no significant teratogenicity signals identified, though first-trimester use lacks sufficient safety data and should be avoided without medical supervision. Individuals with known hypersensitivity to rutin, quercetin, or related flavonoids should avoid troxerutin.
